Clinical trial
A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease
NCT01304277 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease
- Lead sponsor
- Shire
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 17, 2011
- Completion date
- December 28, 2012
- Enrollment
- 17 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.